Should a patient maintained on Suboxone (buprenorphine/naloxone) continue receiving Suboxone while hospitalized and receiving additional pain medication?

Should You Continue Suboxone in Hospitalized Patients Requiring Pain Management?

Yes, continue Suboxone (buprenorphine) in hospitalized patients while adding additional pain medications as needed—discontinuing buprenorphine increases opioid requirements, worsens pain control, and significantly increases relapse risk without improving outcomes. 1, 2

Current Evidence-Based Approach

The most recent high-quality evidence demonstrates that continuing buprenorphine during hospitalization is superior to discontinuation:

• Continuation of buprenorphine does not result in higher pain scores compared to patients without buprenorphine, while interruption leads to significantly worse pain (pain scores: 4.9 for continued vs 5.5 for interrupted buprenorphine, p<0.001) 2

• Patients who continue buprenorphine require similar or lower supplemental opioid doses (39.7 mg morphine equivalents/day) compared to controls (36.5 mg/day), while those who interrupt buprenorphine require nearly double the opioids (74.2 mg morphine equivalents/day, p<0.001) 2

• Continuation is associated with 94% retention in OUD treatment post-discharge, compared to only 63.7% among those who had buprenorphine discontinued near discharge 3

Practical Management Algorithm

For Patients on ≤12 mg Daily Buprenorphine:

• Continue the current buprenorphine dose throughout hospitalization 1
• Add multimodal analgesia: NSAIDs, acetaminophen, gabapentinoids, regional anesthesia where applicable 1
• Add full opioid agonists (morphine, hydromorphone, oxycodone) for breakthrough pain, expecting higher-than-typical doses due to opioid tolerance 4, 2
• Divide the daily buprenorphine dose into every 6-8 hour administration to provide some analgesic effect while maintaining OUD treatment 1, 4

For Patients on >12 mg Daily Buprenorphine:

• Consider tapering to 12 mg sublingual 2-3 days before planned surgery if time permits 1
• Continue buprenorphine at the reduced dose perioperatively 1
• Use aggressive multimodal analgesia and higher doses of full opioid agonists for 2-4 days post-surgery 1

Critical Implementation Points:

• Never abruptly discontinue buprenorphine—this precipitates withdrawal, increases pain perception through hyperalgesia, and dramatically increases relapse risk (15.7% relapse rate even with continuation strategies) 5

• Expect opioid tolerance: Patients will require higher and more frequent doses of full agonist opioids (similar to any opioid-tolerant patient) 1, 4

• Buprenorphine provides minimal acute analgesia at maintenance doses for OUD—it prevents withdrawal but does not treat acute pain effectively, necessitating additional analgesics 4

Common Pitfalls to Avoid

Do not fear "stacking" buprenorphine with full opioid agonists: While buprenorphine has high receptor affinity, full agonists can still provide analgesia when dosed appropriately, and this combination is safer than discontinuation 4, 2, 6

Do not withhold opioids due to addiction concerns: Inadequate pain control does not prevent relapse—in fact, undertreated pain and withdrawal symptoms increase relapse risk significantly 4, 3

Do not assume buprenorphine "blocks" all opioid effects: At maintenance doses (8-24 mg), additional opioids can provide analgesia, though higher doses are required 1, 4

Ensure buprenorphine administration continues through discharge: The final 36 hours before discharge are critical—administration during this window predicts 94% vs 63.7% treatment retention 3

Alternative Approach (Only When Continuation Fails)

If pain remains uncontrolled despite maximized multimodal analgesia and high-dose opioids:

• Convert buprenorphine to methadone 30-40 mg daily to prevent withdrawal while allowing full agonist opioids to work more effectively 4
• Use this only for hospitalized patients where close monitoring is available 4
• Plan buprenorphine reinduction before discharge using standard protocols, ensuring mild withdrawal is present before restarting to avoid precipitated withdrawal 4

Safety Profile

Continuation is safer than discontinuation: Serious adverse events occur less frequently with buprenorphine continuation (OR 0.72,95% CI 0.48-1.09) 7, and no fatal or non-fatal opioid overdoses were observed in patients continuing buprenorphine during acute pain episodes 5

The evidence overwhelmingly supports continuation: Recent 2024-2025 studies consistently demonstrate that continuing buprenorphine results in better pain control, lower opioid requirements, better treatment retention, and comparable safety compared to discontinuation strategies 2, 3, 6, 5